Not to be deterred by COVID-19, Treventis attended the BIO Digital International Convention (formerly scheduled for San Diego, California; instead held digitally) with more than 7,000 attendees and 64 countries represented. This conference hosts delegates passionate about creating new opportunities to partner and collaborate on innovative drug projects aimed at improving the lives of patients.
This year, Treventis CEO Christopher Barden networked with dozens of other companies and partners about the company’s technology and programs in protein misfolding disease therapeutics, including the tremendous progress being made in our oncology program.